Mrukmed.Lekarz Beata Madej-Mruk I Partner sp.p.
- Address
- lock Available on a paid plan
Mrukmed.Lekarz Beata Madej-Mruk I Partner sp.p. - Breast Cancer Research
Mrukmed.Lekarz Beata Madej-Mruk I Partner sp.p. is a clinical research facility specializing in advanced oncology trials, with particular expertise in breast cancer therapeutics. The center focuses on evaluating novel treatment approaches for patients with complex breast cancer presentations, including those with hormone receptor-positive and HER2-positive disease.
- Locally-advanced unresectable and metastatic breast cancer treatment studies
- HER2-positive and estrogen receptor-positive breast cancer research
- Combination therapy trials involving targeted agents and antibody-drug conjugates
The center participates in pivotal trials examining progression-free survival outcomes with innovative therapeutic combinations, including next-generation selective estrogen receptor degraders and subcutaneous HER2-targeted antibody combinations. Their research contributes to advancing treatment options for previously untreated patients with advanced breast cancer, emphasizing both efficacy and safety in real-world clinical settings.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Mrukmed.Lekarz Beata Madej-Mruk I Partner sp.p.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A PHASE III, RANDOMIZED, OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT IN COMBINATION WITH PHESGO VERSUS PHESGO AFTER INDUCTION THERAPY WITH PHESGO+TAXANE IN PATIENTS WITH PREVIOUSLY UNTREATED HER2-POSITIVE, ESTROGEN RECEPTOR-POSITIVE LOCALLY-ADVANCED OR METASTATIC BREAST CANCER | F. Hoffmann-La Roche AG | Phase III | Not Recruiting | Jun 2022 | — |
IMP list
lock Showing 1 of 9 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Anastrozole | 1 | Unknown | 2022-06-24 | 2022-06-24 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.